aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.
Company profile
Ticker
AQST
Exchange
Website
CEO
Keith J. Kendall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MonoSol Rx, Inc.
SEC CIK
Corporate docs
IRS number
208623253
AQST stock data
Latest filings (excl ownership)
8-K
Other Events
22 Apr 24
S-3
Shelf registration
3 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
21 Mar 24
424B5
Prospectus supplement for primary offering
21 Mar 24
424B5
Prospectus supplement for primary offering
19 Mar 24
8-K
Other Events
14 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
5 Mar 24
S-8
Registration of securities for employees
12 Feb 24
Transcripts
AQST
Earnings call transcript
2023 Q4
6 Mar 24
AQST
Earnings call transcript
2023 Q3
7 Nov 23
AQST
Earnings call transcript
2023 Q2
8 Aug 23
AQST
Earnings call transcript
2023 Q1
3 May 23
AQST
Earnings call transcript
2022 Q4
8 Mar 23
AQST
Earnings call transcript
2022 Q3
2 Nov 22
AQST
Earnings call transcript
2022 Q2
3 Aug 22
AQST
Earnings call transcript
2022 Q1
4 May 22
AQST
Earnings call transcript
2021 Q4
9 Mar 22
AQST
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
SC 13G
Venrock Healthcare Capital Partners III, L.P.
1 Apr 24
4
Alexander Mark Schobel
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Daniel Barber
12 Mar 24
4
Peter E. Boyd
12 Mar 24
4
LORI J BRAENDER
12 Mar 24
4
A ERNEST TOTH JR
12 Mar 24
4
Stephen Wargacki
12 Mar 24
4
Cassie Jung
12 Mar 24
4
Alexander Mark Schobel
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.92 mm | 24.92 mm | 24.92 mm | 24.92 mm | 24.92 mm | 24.92 mm |
Cash burn (monthly) | (no burn) | (no burn) | 792.33 k | 1.01 mm | 782.33 k | (no burn) |
Cash used (since last report) | n/a | n/a | 5.40 mm | 6.91 mm | 5.33 mm | n/a |
Cash remaining | n/a | n/a | 19.52 mm | 18.01 mm | 19.59 mm | n/a |
Runway (months of cash) | n/a | n/a | 24.6 | 17.8 | 25.0 | n/a |
Institutional ownership, Q2 2023
30.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 55 |
Opened positions | 25 |
Closed positions | 5 |
Increased positions | 17 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 29.18 bn |
Total shares | 22.55 mm |
Total puts | 800.00 |
Total calls | 36.40 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Bratton Capital Management | 9.81 mm | $16.19 bn |
Douglas K Bratton | 3.47 mm | $13.49 mm |
Vanguard | 1.56 mm | $2.57 bn |
Renaissance Technologies | 1.23 mm | $2.03 mm |
Armistice Capital | 1.16 mm | $1.91 bn |
Vahanian & Associates Financial Planning | 725.21 k | $1.20 bn |
Bracebridge Capital | 428.57 k | $707.14 mm |
Geode Capital Management | 410.98 k | $678.11 mm |
BLK Blackrock | 406.30 k | $670.40 mm |
Walleye Capital | 403.90 k | $666.43 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Alexander Mark Schobel | Common Stock | Sell | Dispose S | No | Yes | 6 | 50,000 | 300.00 k | 984,476 |
10 Mar 24 | Stephen Wargacki | Common Stock | Payment of exercise | Dispose F | No | No | 4.88 | 1,687 | 8.23 k | 257,963 |
10 Mar 24 | Cassie Jung | Common Stock | Payment of exercise | Dispose F | No | No | 4.88 | 1,132 | 5.52 k | 237,754 |
9 Mar 24 | Stephen Wargacki | Common Stock | Payment of exercise | Dispose F | No | No | 4.88 | 11,269 | 54.99 k | 259,650 |
9 Mar 24 | Cassie Jung | Common Stock | Payment of exercise | Dispose F | No | No | 4.88 | 8,300 | 40.50 k | 238,886 |
9 Mar 24 | Barber Daniel | Common Stock | Payment of exercise | Dispose F | No | No | 4.88 | 37,938 | 185.14 k | 845,364 |
9 Mar 24 | Boyd Peter E. | Common Stock | Payment of exercise | Dispose F | No | No | 4.88 | 8,370 | 40.85 k | 237,628 |
News
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
18 Apr 24
Piper Sandler Initiates Coverage On Aquestive Therapeutics with Overweight Rating, Announces Price Target of $10
11 Apr 24
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
5 Apr 24
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
4 Apr 24
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
4 Apr 24
Press releases
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
12 Apr 24
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
25 Mar 24
Thinking about buying stock in Akebia Therapeutics, Boeing, Aquestive Therapeutics, General Electric, or Canoo?
22 Mar 24
Thinking about buying stock in SoundHound AI, Aquestive Therapeutics, Akebia Therapeutics, Kaival Brands, or Lufax?
21 Mar 24
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
19 Mar 24